<DOC>
	<DOCNO>NCT02008357</DOCNO>
	<brief_summary>The purpose study test whether investigational drug call solanezumab slow progression memory problem associate brain amyloid ( protein form plaques brain people Alzheimer Disease [ AD ] ) .</brief_summary>
	<brief_title>Clinical Trial Solanezumab Older Individuals Who May Risk Memory Loss</brief_title>
	<detailed_description>The A4 study clinical trial old individual evidence amyloid plaque build-up brain may risk memory loss cognitive decline due Alzheimer 's disease . The A4 study test anti-amyloid investigational drug old individual yet show symptoms Alzheimer 's disease cognitive impairment dementia aim slow memory cognitive decline . The A4 study also test whether anti-amyloid treatment delay progression AD relate brain injury image biomarkers .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Has MiniMental State Examination ( MMSE ) score screen 25 30 Has global Clinical Dementia Rating ( CDR ) scale score screen 0 Has Logical Memory II score screen 6 18 Has florbetapir positron emission tomography ( PET ) scan show evidence brain amyloid pathology screening Has study partner willing participate source information least weekly contact participant ( contact inperson , via telephone electronic communication ) Is receive prescription acetylcholinesterase inhibitor ( AChEI ) and/or memantine screen baseline Lacks good venous access , intravenous drug delivery multiple blood draw would preclude Has current serious unstable illness include cardiovascular , hepatic , renal , gastroenterologic , respiratory , endocrinologic , neurologic , psychiatric , immunologic , hematologic disease condition , investigator 's opinion , could interfere analysis safety efficacy study Has history within last 5 year serious infectious disease affect brain ( include neurosyphilis , meningitis , encephalitis ) head trauma result protracted loss consciousness Has history within last 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal prostatespecific antigen posttreatment Has know history human immunodeficiency virus ( HIV ) , clinically significant multiple severe drug allergy , severe posttreatment hypersensitivity reaction ( include , limited , erythema multiforme major , linear immunoglobulin A dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) Is clinically judged investigator serious risk suicide Has history within past 2 year major depression bipolar disorder define current version Diagnostic Statistical Manual Mental Disorders ( DSM ) Has history within past 5 year chronic alcohol drug abuse/dependence define current version DSM</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Prevention</keyword>
</DOC>